

## Programme Overview

Friday, November 12, 2010

08:50-09:00	Welcome - Jim Bonner
9:00-09:50	<b>Opening keynote lecture (moderator: Jim Bonner)</b>
	HPV-associated cancers on the rise, a growing problem? - Margaret Stanley
09:50-10:20	<b>Coffee break</b>
10:20-12:00	<b>Joint session (moderator: Margaret Stanley)</b>
	<b>HPV vaccines: current issues in HPV-associated cancers</b>
10:20	Screening women vaccinated for HPV16/18 - Jack Cuzick
10:45	Vaccination for boys: the paediatrician's perspective - Hal Jenson
11:10	Community randomised Phase IV HPV vaccination effectiveness trial: Baseline characteristics and trial deliverables - Matti Lehtinen
11:35	Vaccine development in the developing world - John Sellors
12:00	Session ends
12:00-13:30	<b>Lunch break</b>
13:30-15:10	<b>Parallel session (moderator: Chris Meijer)</b>
	<b>Risk assessment and treatment in cervical cancer</b>
13:30	Management of screen-detected HPV-positive women- Guglielmo Ronco
13:55	Risk of high-grade CIN in women with HPV infection: role of persistence and genotyping - Nicolas Wentzensen
14:20	Organisation of HPV-based screening - Ahti Anttila
14:45	Age issues in HPV screening - Guglielmo Ronco
15:10	Session ends



**THE LANCET** Conferences  
**HPV and Cancer**

Latest professional practice. Future clinical management

November 12 – 13, 2010, Amsterdam, The Netherlands

[www.thelancetconferences.com/hpv-and-cancer/](http://www.thelancetconferences.com/hpv-and-cancer/)

13:30-15:10	<b>Parallel session (moderator: Maura Gillison)</b>
	<b>New agents in head and neck cancer</b>
13:30	HPV and incidence trends for head and neck cancer - Anil Chaturvedi
13:55	The new era of targeted agents in head and neck cancer - Jim Bonner
14:20	Side effects of the new targeted agents in head and neck cancer - Jean Pierre Armand
14:45	Critical assessment of the role of chemotherapy, surgery, and radiation therapy in HPV-related oropharyngeal cancer and future clinical trials - Marshall Posner
15:10	Session ends
15:10-15:40	<b>Tea break</b>
15:40-17:20	<b>Joint session (moderator: Marshall Posner)</b>
	<b>Clinical trial design in relation to HPV-associated disease</b>
15:40	HPV and clinical trial design for head and neck cancer - Maura Gillison
16:05	The importance of window of opportunity studies - Jan Vermorken
16:30	Long-term efficacy of HPV vaccination against hard end-points: Cancer registry based follow-up of phase III efficacy trials - Jorma Paavonen
16:55	Ecological competition of vaccine-type and non-vaccine-type HPVs before and after mass vaccination - Matti Lehtinen
17:20	Session ends
17:20	End of day



**THE LANCET** Conferences  
**HPV and Cancer**

Latest professional practice. Future clinical management  
 November 12 – 13, 2010, Amsterdam, The Netherlands  
[www.thelancetconferences.com/hpv-and-cancer/](http://www.thelancetconferences.com/hpv-and-cancer/)

**Saturday, November 13, 2010**

9:00-10:40	<b>Parallel session (moderator: Jorma Paavonen)</b>
	<b>HPV testing, translational research, and the clinic</b>
09:00	HPV testing in the developing world - John Sellors
09:25	Use of biomarkers in HPV screening programmes - Nicolas Wentzensen
09:50	Is HPV prognostic, predictive, or both? - Lisa Licitra
10:15	Therapeutic HPV vaccines - Cornelia Trimble
10:40	Session ends
9:00-10:40	<b>Parallel session (moderator: Jens Overgaard)</b>
	<b>Management of mouth and oral-pharyngeal cancers in relation to HPV</b>
09:00	Prevalence, natural history, and transmission of oral HPV in relation to oropharyngeal cancer- Gypsyamber Dsouza
09:25	HPV-specific genetic markers in HPV-associated head and neck and cervical cancers- Peter Snijders
09:50	Neck dissection in the surgical management of oropharyngeal cancer: controversies and outstanding questions - TBD
10:15	Evolving treatment paradigms in the management of oropharyngeal cancer - Maura Gillison
10:40	Session ends
10:40-11:10	<b>Coffee break</b>
11:10-12:25	<b>Joint session (moderator: Joel Palefsky)</b>
	<b>Genetics, environment, and lifestyle factors</b>
11:10	HPV infection in pregnancy: issues in relation to prophylactic and therapeutic strategies - Jorma Paavonen
11:35	Co-morbidity and smoking behaviour in HPV positive and negative HNSCC patients in relation to outcome - Jens Overgaard



**THE LANCET** Conferences  
**HPV and Cancer**

Latest professional practice. Future clinical management

November 12 – 13, 2010, Amsterdam, The Netherlands

[www.thelancetconferences.com/hpv-and-cancer/](http://www.thelancetconferences.com/hpv-and-cancer/)

12:00	Race and ethnicity in HPV-related oropharyngeal cancer - Kevin Cullen
12:25	Session ends
12:25-14:00	<b>Lunch break</b>
14:00-15:15	<b>Parallel session (moderator: Guglielmo Ronco)</b>
	<b>Penile and anal cancers: biology and current management</b>
14:00	Prevention and treatment approaches to AIN and anal cancer - Joel Palefsky
14:25	Prophylactic vaccines for anogenital cancer - Margaret Stanley
14:50	Circumcision for prevention of ano-genital and oral cancers? - Tim Oliver
15:15	Session ends
14:00-15:15	<b>Parallel session (moderator: Jean Pierre Armand)</b>
	<b>Radiation in HPV-infected head and neck and oral-pharyngeal cancers</b>
14:00	Radiation in HPV-infected head and neck and oral pharyngeal cancers - Pernille Lassen
14:25	Rationale for radiation dose reduction in HPV-related oropharyngeal cancer - Marshall Posner
14:50	Hypoxia, HPV, and radiotherapy: interactions and implications for outcome - Jens Overgaard
15:15	Session ends
15:20-16:10	<b>Closing keynote lecture (moderator: Jim Bonner)</b>
	HPV infection in the HIV-positive host: molecular interactions and clinical implications - Joel Palefsky
16:10-16:20	Closing remarks - Jim Bonner

**Programme is correct at time of publication**